Drugs / Fluzone High-Dose Quadrivalent
last change Jun 2025 re-read 2 minutes ago

Fluzone High-Dose Quadrivalent

Vaccine

Developed for
influenza
Investigated by
Sanofi Pasteur, a Sanofi Company

Trials 2 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03698279 Oct 2018 → Oct 2019 influenza Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 41 trial
Phase 4 NCT05050318 Sep → Nov 2021 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/23 trials
Phase 1/2 NCT06361875 Comparator Apr 2024 → Jun 2025 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 1/2 NCT05650554 Comparator Dec 2022 → Apr 2024 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 1/2 NCT05553301 Comparator Oct 2022 → Jan 2024 Sanofi Pasteur, a Sanofi Company Completed No outcome recorded
Phase 41 trial
Phase 4 NCT05007041 Comparator Sep 2021 → Mar 2023 Duke University Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2022-06-22 Sanofi Media Update: Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older sanofi.com

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Fluzone High-Dose Quadrivalent “Quadrivalent high-dose inactivated influenza vaccine (Fluzone® High-Dose Quadrivalent, IIV4-HD) was licensed in the USA in 2019 for adults ≥ 65 years of age.” PMID 33610374 Feb 2021
3

Fluzone High-Dose QuadrivalentNCT05050318

NCT05050318

NCT05007041

Known as IIV4-HD “Quadrivalent high-dose inactivated influenza vaccine (Fluzone® High-Dose Quadrivalent, IIV4-HD) was licensed in the USA in 2019 for adults ≥ 65 years of age.” PMID 33610374 Feb 2021
Known as Quadrivalent Influenza High-Dose Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650554
2

NCT06361875

NCT05553301

Modality Vaccine “Quadrivalent high-dose inactivated influenza vaccinePMID 33610374 Feb 2021
Route Intramuscular “received 1 or 2 doses intramuscularly” PMID 33610374 Feb 2021